Indian drug makers seek government protection from cheap Chinese APIs
This article was originally published in Scrip
Executive Summary
Indian firms say that "unhealthy competition" from China is eroding their edge in the production of active pharmaceutical ingredients (APIs), raising the country's dependence on its neighbour for low cost supplies.